Please assess the completion status of the following clinical trial:

Trial Title: IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each of the following criteria must be fulfilled for a subject to be eligible:~1. Age ≥ 18 years~2. OHCA of a presumed cardiac cause~3. Unconsciousness upon admission, i.e. a GCS \< 9~4. Sustained ROSC for more than 20 minutes~Exclusion Criteria:~None of the following criteria must be fulfilled for a subject to be eligible:~1. Consciousness upon admission, i.e. a GCS ≥ 9~2. Presumed non-cardiac cause of arrest~3. Unwitnessed asystole~4. Suspected or confirmed intracranial bleeding or stroke~5. Pregnancy, or females in fertile age, unless a negative serum HCG can rule out pregnancy within the inclusion window.~6. Temperature on admission \< 30 °C~7. Persistent cardiogenic shock\* that is not reversed within the inclusion window~8. Known disease making 180 day survival unlikely~9. Known limitations in therapy~10. Known pre-arrest Cerebral Performance Category of 3 to 4~11. \> 240 minutes from ROSC to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: ACTIVE_COMPARATOR): A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
- Isotonic saline (Type: PLACEBO_COMPARATOR): A one hour infusion of isotonic saline

Based on this trial design, predict the completion outcome and termination type (if applicable).